This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Sotalol

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Sotalol is a beta blocker and a potassium channel blocker; it thus is an antiarrhythmic falling into two classes of the Vaughan Williams classification.

Like other beta blockers, sotalol decreases the heart rate via slowing of conduction in the atrioventricular node.

Unlike other beta blockers sotalol lengthens the duration of monophasic action potentials in the atria and the ventricles. The drug prolongs refractoriness not only in atrial and ventricular myocardium but also in the atrioventricular node, the His - Purkinje system, and atrioventricular bypass tracts. Also it has less of a negative ionotropic effect than other beta blockers (1).

Diuretics and hypokalaemia should be avoided when using sotalol (1).

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  • Committee on Safety of Medicines (1996). Restricted indications for sotalol (Sotacar, Beta-Cardone). Current Problems in Pharmacovigilance, 22, 6-7.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.